Literature DB >> 1737161

Octreotide and Graves' ophthalmopathy and pretibial myxoedema.

T C Chang1, S C Kao, K M Huang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1737161      PMCID： PMC1881144          DOI： 10.1136/bmj.304.6820.158

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

Review 2.  Pathogenesis and treatment of pretibial myxedema.

Authors:  J P Kriss
Journal:  Endocrinol Metab Clin North Am       Date:  1987-06       Impact factor: 4.741

3.  Somatomedin C in pathogenesis of malignant exophthalmos of endocrine origin.

Authors:  H A Hansson; B Petruson; A Skottner
Journal:  Lancet       Date:  1986-01-25       Impact factor: 79.321

4.  Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells.

Authors:  S Tsuzaki; A C Moses
Journal:  Endocrinology       Date:  1990-06       Impact factor: 4.736
  4 in total
  11 in total

Review 1.  Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.

Authors:  C Marcocci; M Marinò; R Rocchi; F Menconi; E Morabito; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

2.  Octreotide and Graves' ophthalmopathy.

Authors:  P Perros; R A James; P Kendall-Taylor
Journal:  BMJ       Date:  1992-02-22

3.  Octreotide and urinary glycosaminoglycan in Graves' disease.

Authors:  T C Chang; W C Yao; C C Chang
Journal:  BMJ       Date:  1992-05-30

4.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

5.  Somatostatin-receptor scintigraphy in Graves' orbitopathy.

Authors:  P T Postema; D J Kwekkeboom; P M van Hagen; E P Krenning
Journal:  Eur J Nucl Med       Date:  1996-06

6.  The cost of immunosuppressive therapies currently used in patients with thyroid eye disease.

Authors:  G E Krassas
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

7.  Locally produced insulin-like growth factor-1 by orbital fibroblasts as implicative pathogenic factor rather than systemically circulated IGF-1 for patients with thyroid-associated ophthalmopathy.

Authors:  Delu Song; Renyan Wang; Yong Zhong; Weiye Li; Hui Li; Fangtian Dong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-09       Impact factor: 3.117

Review 8.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

9.  The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease.

Authors:  Gerasimos E Krassas; Themistoklis Tzotzas; Konstantinos Papazisis; Kaliopi Pazaitou-Panayiotou; Kostas Boboridis
Journal:  Clin Ophthalmol       Date:  2007-09

10.  Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.

Authors:  Deng-Huang Su; Ying-Chun Chang; Shu-Lang Liao; Tien-Chun Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09-28       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.